Spots Global Cancer Trial Database for Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
Official Title: A Phase 2b Randomized Trial of Autologous Dendritic Cell Immunotherapy (CMN-001) Plus Standard Treatment of Advanced Renal Cell Carcinoma
Study ID: NCT04203901
Conditions
Study Description
Brief Summary: CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st line failure.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Emory University, Atlanta, Georgia, United States
Mayo Clinic, Rochester, Minnesota, United States
SUNY Upstate Medical University, Syracuse, New York, United States
Westchester Medical Center, Valhalla, New York, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Houston Methodist, Houston, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
West Virginia University Cancer Institute, Morgantown, West Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
